Loss of mGluR5 in D1 Receptor-Expressing Neurons Improves Stress Coping.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
22 Jul 2021
Historique:
received: 25 05 2021
revised: 11 07 2021
accepted: 19 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 17 8 2021
Statut: epublish

Résumé

The metabotropic glutamate receptor type 5 (mGluR5) has been proposed to play a crucial role in the selection and regulation of cognitive, affective, and emotional behaviors. However, the mechanisms by which these receptors mediate these effects remain largely unexplored. Here, we studied the role of mGluR5 located in D1 receptor-expressing (D1) neurons in the manifestation of different behavioral expressions. Mice with conditional knockout (cKO) of mGluR5 in D1 neurons (mGluR5

Identifiants

pubmed: 34360592
pii: ijms22157826
doi: 10.3390/ijms22157826
pmc: PMC8346057
pii:
doi:

Substances chimiques

Grm5 protein, mouse 0
Receptor, Metabotropic Glutamate 5 0
Receptors, Dopamine D1 0
Dopamine VTD58H1Z2X

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Austrian Science Fund
ID : W12060-B10
Organisme : Austrian Science Fund
ID : W12060-B12
Organisme : Deutsche Forschungsgemeinschaft
ID : GO-Bio

Références

Biol Psychiatry. 2015 Feb 1;77(3):212-222
pubmed: 25173629
Cell. 2007 Oct 19;131(2):391-404
pubmed: 17956738
Neuropsychopharmacology. 2007 Mar;32(3):562-76
pubmed: 16794564
Curr Opin Neurobiol. 2011 Jun;21(3):502-8
pubmed: 21501959
Psychopharmacology (Berl). 2006 Sep;187(4):455-66
pubmed: 16835771
J Neurosci. 2019 Apr 3;39(14):2745-2761
pubmed: 30737312
Nat Neurosci. 2015 Mar;18(3):435-43
pubmed: 25622145
J Neurosci. 2020 Sep 16;40(38):7241-7254
pubmed: 32847967
CNS Drugs. 2010 Aug;24(8):669-93
pubmed: 20658799
Curr Psychiatry Rep. 2007 Oct;9(5):388-95
pubmed: 17915078
Biol Psychiatry. 2006 Jun 15;59(12):1151-9
pubmed: 16566899
Science. 2006 Feb 10;311(5762):864-8
pubmed: 16469931
Chronic Stress (Thousand Oaks). 2017 Jan-Dec;1:
pubmed: 28884167
Neuropharmacology. 2008 Apr;54(5):837-44
pubmed: 18272187
Brain Res Bull. 2011 Oct 10;86(3-4):152-8
pubmed: 21840381
J Neurosci. 2005 Apr 13;25(15):3763-73
pubmed: 15829628
Psychoneuroendocrinology. 2020 Mar;113:104542
pubmed: 31862611
Neuropharmacology. 2011 Jun;60(7-8):1017-41
pubmed: 21036182
J Neurosci. 2017 Apr 19;37(16):4225-4227
pubmed: 28424298
PLoS One. 2013 Aug 05;8(8):e70415
pubmed: 23940572
Nat Rev Drug Discov. 2005 Feb;4(2):131-44
pubmed: 15665858
ACS Chem Neurosci. 2017 May 17;8(5):955-960
pubmed: 28287253
iScience. 2020 Mar 27;23(3):100951
pubmed: 32179475
Biol Psychiatry. 2013 Feb 1;73(3):263-70
pubmed: 22902169
Front Behav Neurosci. 2014 Sep 24;8:317
pubmed: 25309368
Neurosci Biobehav Rev. 2014 Oct;46 Pt 2:228-41
pubmed: 24548786
Mol Psychiatry. 2015 Dec;20(12):1546-56
pubmed: 26370144
J Pharmacol Exp Ther. 2006 Oct;319(1):254-9
pubmed: 16803860
Neuropharmacology. 2007 Nov;53(6):741-8
pubmed: 17870136
Drug News Perspect. 2005 Jul-Aug;18(6):353-61
pubmed: 16247513
Brain Behav Immun. 2017 Jan;59:79-92
pubmed: 27524668
Neural Plast. 2016;2016:6503162
pubmed: 27034848
Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8390-8395
pubmed: 28716937
J Neurosci. 2009 Mar 25;29(12):3676-84
pubmed: 19321764
Nat Neurosci. 2015 Jul;18(7):1017-24
pubmed: 26005851
J Neurosci. 2010 Sep 8;30(36):11973-82
pubmed: 20826661
J Neurosci. 2011 Mar 16;31(11):4280-9
pubmed: 21411669
Neuropsychopharmacology. 2015 Sep;40(10):2337-46
pubmed: 25824423
Front Psychiatry. 2013 Sep 12;4:100
pubmed: 24062696
Front Mol Neurosci. 2019 Feb 19;12:30
pubmed: 30873001
J Neurosci. 2010 Dec 15;30(50):16896-909
pubmed: 21159961
Genes Brain Behav. 2004 Oct;3(5):303-14
pubmed: 15344923
Biol Psychiatry. 2002 May 15;51(10):775-87
pubmed: 12007451
J Neurosci. 2014 Mar 26;34(13):4728-40
pubmed: 24672017
Neurosci Biobehav Rev. 2001 Dec;25(7-8):669-78
pubmed: 11801292
Neuropharmacology. 2004 Sep;47(3):342-50
pubmed: 15275823
Nat Commun. 2019 Jan 15;10(1):223
pubmed: 30644390
Br J Pharmacol. 2001 Apr;132(7):1423-30
pubmed: 11264235
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1129-35
pubmed: 16759778
Curr Opin Pharmacol. 2018 Feb;38:37-42
pubmed: 29494817
Front Pharmacol. 2018 Nov 13;9:1306
pubmed: 30483137
Mol Neurobiol. 2019 Jun;56(6):4037-4050
pubmed: 30259400
Neurobiol Dis. 2019 May;125:55-66
pubmed: 30677495
Neuroscience. 2012 Feb 17;203:59-77
pubmed: 22210508
J Neurosci. 2013 Nov 20;33(47):18381-95
pubmed: 24259563
J Exp Psychol. 1967 May;74(1):1-9
pubmed: 6032570
Biol Psychiatry. 2010 Nov 1;68(9):785-94
pubmed: 20728076
Am J Psychiatry. 2011 Jul;168(7):727-34
pubmed: 21498461
Neurosci Biobehav Rev. 2012 Jan;36(1):79-89
pubmed: 21565217
Neurosci Biobehav Rev. 2020 Nov;118:739-758
pubmed: 32916193
Nature. 2012 Jul 11;487(7406):183-9
pubmed: 22785313
Nature. 2003 Oct 30;425(6961):917-25
pubmed: 14586460
Psychol Rev. 2016 Jul;123(4):349-67
pubmed: 27337390
Pharmacol Res. 1993 Jul-Aug;28(1):53-8
pubmed: 8234145
Behav Brain Res. 2013 Mar 15;241:27-31
pubmed: 23228523
Int J Neuropsychopharmacol. 2014 Dec;17(12):1915-22
pubmed: 24833114
Nature. 2013 Jan 24;493(7433):532-6
pubmed: 23235832
J Neurosci. 2007 Sep 12;27(37):9817-23
pubmed: 17855595
Sci Transl Med. 2012 Apr 25;4(131):131ra51
pubmed: 22539775
Behav Brain Res. 2013 Feb 15;239:72-9
pubmed: 23142366
Nat Neurosci. 2009 Feb;12(2):190-9
pubmed: 19169252
Trends Pharmacol Sci. 2019 Apr;40(4):240-252
pubmed: 30824180
Nat Rev Neurosci. 2015 May;16(5):290-304
pubmed: 25891510
Mol Psychiatry. 2015 Oct;20(10):1161-72
pubmed: 26260494
Neuron. 2015 Mar 18;85(6):1319-31
pubmed: 25754825
Biol Psychiatry. 2017 Apr 15;81(8):645-653
pubmed: 27871668

Auteurs

Luca Zangrandi (L)

Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
Institute of Pharmacology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Claudia Schmuckermair (C)

Institute of Pharmacology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Hussein Ghareh (H)

Department of Psychiatry 1, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Federico Castaldi (F)

Institute of Pharmacology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Regine Heilbronn (R)

Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.

Gerald Zernig (G)

Department of Psychiatry 1, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Francesco Ferraguti (F)

Institute of Pharmacology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Arnau Ramos-Prats (A)

Institute of Pharmacology, Medical University of Innsbruck, 6020 Innsbruck, Austria.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH